Journal of Clinical Psychopharmacology最新文献

{"title":"Antipsychotic Treatment Approaches in Schizophrenia Spectrum and Other Psychotic Disorders: Prescription Patterns in Eight Different Diagnostic Groups.","authors":"Sönke Johann Peters, Ana Staninska, Isabell Lehmann, Euphrosyne Gouzoulis-Mayfrank","doi":"10.1097/JCP.0000000000002079","DOIUrl":"10.1097/JCP.0000000000002079","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to characterize real-world prescription patterns of antipsychotic drugs in patients with various psychiatric disorders with psychotic features.</p><p><strong>Method: </strong>We analyzed the discharge prescription plans of 59,962 cases with the main diagnoses schizophrenia, schizoaffective disorder, acute transient psychotic disorder, delusional disorder, psychotic bipolar disorder, psychotic depression, organic delusional disorder or substance-induced psychosis. We analyzed the overall use, pharmacological subgroups, the use of long-acting injectable (LAI) formulations, and the frequency of prescription of the singular antipsychotic drugs.</p><p><strong>Results: </strong>Significant differences in prescribing patterns were observed across diagnoses, though effect sizes were generally low. Overall, second-generation antipsychotics (SGA) were most frequently prescribed. Patients with schizophrenia and schizoaffective disorder (SAD) were the groups with the highest use of high-potency first-generation antipsychotics (FGA). LAIs and clozapine were most used in schizophrenia. Quetiapine was favoured in psychotic bipolar disorder and psychotic depression, while risperidone was common in delusional and organic delusional disorder.</p><p><strong>Conclusion: </strong>Patients with SAD could potentially benefit from higher rates of LAI and clozapine prescriptions. Also, current prescribing practices in patients with psychotic depression may not adequately consider the potential benefits of LAI antipsychotics. Regarding the previously mentioned prescription preferences, further research on the comparative effectiveness of different antipsychotics for these patient groups is warranted.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender Differences in Psychotropic Medication Use: A Naturalistic Study Among Psychiatric Outpatients in Secondary Care.","authors":"Edith J Liemburg, Klaas J Wardenaar, Sanne Krol, Maaike M van Veen, Bennard Doornbos, Arne Risselada, Danielle C Cath","doi":"10.1097/JCP.0000000000002083","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002083","url":null,"abstract":"<p><strong>Purpose/background: </strong>Previous studies among psychiatric patients have shown differences between men and women in psychotropic medication prescription patterns. The factors underlying these differences are still poorly understood. This exploratory study aimed to investigate a range of clinical and demographic factors in their contributions to explaining these gender differences.</p><p><strong>Methods/procedures: </strong>In 2476 outpatients with a mental disorder (mean age 46.1 year, 58.2% women) enrolled in pharmacotherapy monitoring program, regression analyses were used to investigate the associations of gender with use of any psychotropic (yes/no), use of each separate psychotropic type (yes/no), number (0 to 4) and dosage of each used psychotropic. Next, clinical and demographic effect modifiers and explanatory/confounding factors of these associations were identified.</p><p><strong>Findings/results: </strong>Frequencies of general psychotropic use, antidepressant use, anxiolytic use, as well as polypharmacy were significantly higher in women than in men across all ages (premenopausal, perimenopausal, and postmenopausal), with equal dosing of psychotropics, except for higher doses of mood stabilizers in men. Longer illness duration and having a partner were effect modifiers of the gender effect, while higher frequencies of an affective/anxiety diagnosis, higher somatic complaints and symptomatic distress, more previous mental health service (MHS) visits and no current occupation were explanatory factors.</p><p><strong>Implications/conclusions: </strong>Psychotropic use and psychotropic polypharmacy were more common in women than in men. Women on psychotropic medications were more often diagnosed with affective/anxiety diagnoses, experienced more symptomatic distress and somatic complaints, and visited more healthcare services than men, reaffirming findings from previous studies. Future longitudinal studies should investigate in further detail whether these outcomes are cause or consequence of gender differences in psychotropic medication use.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Interaction Between Clozapine and Rifampicin: Experience in Management Strategies From a Case Report.","authors":"Juan Tortajada-Valero, Lorena Chavez-Pino, Helen Nguyen, Kate Dennis, Kirsten Rust, Zahoor Syed, Natalia Ghirasim, Christopher Jenkins, Emilio Fernandez-Egea","doi":"10.1097/JCP.0000000000002063","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002063","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Rifampicin on Serum Clozapine Concentration/Daily Dose (C/D) Ratio: Case Series and Literature Review.","authors":"Veena Ramesh, Anusha M Nagaraj, Likhita P Tippeswamy, Ranjitha Ramachandraiah, Gautam Sudhakar N, Pavithra Jayasankar, Vijay Kumar","doi":"10.1097/JCP.0000000000002077","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002077","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limitations in Recent Study of Clozapine Use During Pregnancy.","authors":"Karrar Husain, Abid Rizvi, Sahar Ashraf, Shailesh Jain","doi":"10.1097/JCP.0000000000002081","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002081","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Limitations in Recent Study of Clozapine Use During Pregnancy\".","authors":"Sandeep Grover, Surabhi Gupta","doi":"10.1097/JCP.0000000000002085","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002085","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter Bioavailability Study of Long-Acting Paliperidone in Patients With Schizophrenia or Schizoaffective Disorder.","authors":"Thalita Martins da Silva, Débora Renz Barreto Vianna, Jessica Meulman, Ryan Turncliff, Fernando Costa, Celso Francisco Pimentel Vespasiano","doi":"10.1097/JCP.0000000000002078","DOIUrl":"10.1097/JCP.0000000000002078","url":null,"abstract":"<p><strong>Purpose/background: </strong>Schizophrenia is often associated with nonadherence to oral antipsychotic therapy, which increases the risk of relapse, hospitalization, and higher health care costs. To overcome this challenge, long-acting injectable (LAI) antipsychotics, such as paliperidone palmitate, offer a solution by reducing relapse rates. Also, the bioequivalent formulations can enhance treatment accessibility while maintaining efficacy and safety. The present study assessed the bioequivalence of a test paliperidone palmitate extended-release injectable suspension (PP-ERIS), Vegapali, compared with the reference formulation, Invega Sustenna.</p><p><strong>Methods/procedures: </strong>A multicenter, randomized, multiple-dose, open-label, parallel-arm pharmacokinetic (PK) study was conducted including patients with schizophrenia or schizoaffective disorder receiving monthly intramuscular injections of the test or reference formulation for 7 months. Plasma samples were collected predose and postdose to determine steady-state PK parameters, including C max,ss and AUC τ,ss . The bioequivalence was confirmed if the 90% CIs for the test/reference geometric mean ratios were within 80.00% to 125.00%. Safety assessments also included adverse event (AE) monitoring and clinical evaluations.</p><p><strong>Findings/results: </strong>The PK analysis demonstrated that the 90% CIs for Cmax,ss and AUCτ,ss were within the required bioequivalence range. Both formulations exhibited comparable systemic exposure, and AE incidence was consistent with the known safety profile of paliperidone palmitate.</p><p><strong>Implications/conclusions: </strong>The test formulation, Vegapali, proved to be bioequivalent to the reference product, supporting its use as an alternative LAI treatment for schizophrenia. This finding guarantees the therapeutic equivalence of both formulations, expanding access to effective and sustained treatment options for schizophrenia management.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asymptomatic Adrenal Insufficiency Associated With Quetiapine and Megestrol: A Case Report.","authors":"Yinghui Xie, Yunchuan Ding, Huijing Mei, Shengliang Wu","doi":"10.1097/JCP.0000000000002082","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002082","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With Depression.","authors":"Renee E Albers, Melissa P Dyer, Matthew Kucera, Daniel Hain, Alexander Gutin, Andria L Del Tredici, Rachael H Earls, Sagar V Parikh, Holly L Johnson, Rebecca Law, Boadie W Dunlop","doi":"10.1097/JCP.0000000000002061","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002061","url":null,"abstract":"<p><strong>Purpose/background: </strong>Multiple meta-analyses have suggested that pharmacogenomic (PGx) testing may be a valuable tool to improve clinical outcomes for patients with major depressive disorder (MDD) who have failed at least one treatment. However, these meta-analyses included studies with different PGx tests and different trial designs, which produce uncertainty when interpreting results. To investigate the clinical utility of a single weighted multigene PGx test, a meta-analysis was performed for prospective studies utilizing this PGx test in adult patients with MDD.</p><p><strong>Methods/procedures: </strong>MEDLINE/PubMed and Cochrane [including Embase, clinicaltrials.gov, and International Clinical Trials Registry Platform (ICTRP)] were searched through May 2025 for studies evaluating the impact of pharmacogenomic testing on outcomes for patients with MDD. Using PRISMA guidelines, 243 records were identified, and 6 studies were included that compared PGx-guided care to unguided care in adult patients with MDD, using a single weighted multigene test.</p><p><strong>Findings/results: </strong>Overall, 3,532 patients were included, with outcomes evaluated at week 8 or week 10. Patients with MDD whose care was guided by the weighted multigene PGx test were 30% more likely to achieve response [relative risk ratio (RR)=1.30, 95% CI: 1.16-1.47, P<0.001] and 41% more likely to achieve remission [RR=1.41, 95% CI: 1.19-1.66, P<0.001] compared to unguided care. No heterogeneity in outcomes across studies was detected.</p><p><strong>Implications/conclusions: </strong>Prescribing informed by a weighted multigene PGx test significantly improved response and remission rates among adult patients with MDD who experienced at least 1 prior treatment failure, further demonstrating the clinical utility of weighted multigene PGx testing.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"All Patients With Catatonia Deserve Proper Diagnosis, Theragnosis, and Prognosis\".","authors":"Alexandra Rockett, Andrew Stoner, Catherine Ironbar, Joseph Chien","doi":"10.1097/JCP.0000000000002039","DOIUrl":"10.1097/JCP.0000000000002039","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"532-533"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}